Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - rivastigmine
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpe0ec42c68686885cc176ad73b71e1d80
identifier: http://ema.europa.eu/identifier
/EU/1/09/599/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Rivastigmine Sandoz 1.5 mg hard capsules
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-e0ec42c68686885cc176ad73b71e1d80
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/09/599/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - rivastigmine
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
The active substance of Rivastigmine Sandoz is rivastigmine.
Rivastigmine belongs to a class of substances called cholinesterase inhibitors. In patients with Alzheimer s dementia or dementia due to Parkinson s disease, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other). Rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase. By blocking these enzymes, Rivastigmine Sandoz allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer s disease and dementia associated with Parkinson s disease.
Rivastigmine Sandoz is used for the treatment of adult patients with mild to moderately severe Alzheimer s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour. The capsules and oral solution can also be used for the treatment of dementia in adult patients with Parkinson s disease.
Do not take Rivastigmine Sandoz
If this applies to you, tell your doctor and do not take Rivastigmine Sandoz.
Warnings and precautions
Talk to your doctor before taking Rivastigmine Sandoz
If any of these apply to you, your doctor may need to monitor you more closely while you are on this medicine.
If you have not taken Rivastigmine Sandoz for more than three days, do not take the next dose until you have talked to your doctor.
Children and adolescents
There is no relevant use of Rivastigmine Sandoz in the paediatric population in the treatment of Alzheimer s disease.
Other medicines and Rivastigmine Sandoz Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Rivastigmine Sandoz should not be given at the same time as other medicines with similar effects to Rivastigmine Sandoz. Rivastigmine Sandoz might interfere with anticholinergic medicines (medicines used to relieve stomach cramps or spasms, to treat Parkinson s disease or to prevent travel sickness). Rivastigmine Sandoz should not be given at the same time as metoclopramide (a medicine used to relieve or prevent nausea and vomiting). Taking the two medicines together could cause problems such as stiff limbs and trembling hands.
If you have to undergo surgery whilst taking Rivastigmine Sandoz, tell your doctor before you are given any anaesthetics, because Rivastigmine Sandoz may exaggerate the effects of some muscle relaxants during anaesthesia.
Caution when Rivastigmine Sandoz is taken together with beta-blockers (medicines such as atenolol used to treat hypertension, angina and other heart conditions). Taking the two medicines together could cause problems such as slowing of the heartbeat (bradycardia) leading to fainting or loss of consciousness.
Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
If you are pregnant, the benefits of using Rivastigmine Sandoz must be assessed against the possible effects on your unborn child. Rivastigmine Sandoz should not be used during pregnancy unless clearly necessary.
You should not breast-feed during treatment with Rivastigmine Sandoz.
Driving and using machines Your doctor will tell you whether your illness allows you to drive vehicles and use machines safely. Rivastigmine Sandoz may cause dizziness and somnolence, mainly at the start of treatment or when increasing the dose. If you feel dizzy or sleepy, do not drive, use machines or perform any tasks that require your attention.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
How to start treatment Your doctor will tell you what dose of Rivastigmine Sandoz to take
Treatment usually starts with a low dose.
Your doctor will slowly increase your dose depending on how you respond to treatment.
The highest dose that should be taken is 6.0 mg twice a day.
Your doctor will regularly check if the medicine is working for you. Your doctor will also monitor your weight whilst you are taking this medicine.
If you have not taken Rivastigmine Sandoz for more than three days, do not take the next dose until you have talked to your doctor.
Taking this medicine
Tell your caregiver that you are taking Rivastigmine Sandoz.
To benefit from your medicine, take it every day.
Take Rivastigmine Sandoz twice a day in the morning and evening with food.
Swallow the capsules whole with a drink.
Do not open or crush the capsules.
If you take more Rivastigmine Sandoz than you should If you accidentally take more Rivastigmine Sandoz than you should, inform your doctor. You may require medical attention. Some people who have accidentally taken too much Rivastigmine Sandoz have experienced feeling sick (nausea), being sick (vomiting), diarrhoea, high blood pressure and hallucinations. Slow heartbeat and fainting may also occur.
If you forget to take Rivastigmine Sandoz If you find you have forgotten to take your dose of Rivastigmine Sandoz, wait and take the next dose at the usual time. Do not take a double dose to make up for a forgotten dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
You may have side effects more often when you start your medicine or when your dose is increased. Usually, the side effects will slowly go away as your body gets used to the medicine.
Very common (may affect more than 1 in 10 people)
Feeling dizzy
Loss of appetite
Stomach problems such as feeling sick (nausea) or being sick (vomiting), diarrhoea
Common (may affect up to 1 in 10 people)
Anxiety
Sweating
Headache
Heartburn
Weight loss
Stomach pain
Feeling agitated
Feeling tired or weak
Generally feeling unwell
Trembling or feeling confused
Decreased appetite
Nightmares
Uncommon (may affect up to 1 in 100 people)
Depression
Difficulty in sleeping
Fainting or accidentally falling
Changes in how well your liver is working
Rare (may affect up to 1 in 1,000 people)
Chest pain
Rash, itching
Fits (seizures)
Ulcers in your stomach or intestine
Very rare (may affect up to 1 in 10,000 people)
High blood pressure
Urinary tract infection
Seeing things that are not there (hallucinations)
Problems with your heartbeat such as fast or slow heartbeat
Bleeding in the gut shows as blood in stools or when being sick
Inflammation of the pancreas the signs include serious upper stomach pain, often with feeling sick (nausea) or being sick (vomiting)
The signs of Parkinson s disease get worse or getting similar signs such as stiff muscles, difficulty in carrying out movements
Not known (frequency cannot be estimated from the available data)
Being violently sick (vomiting) that can cause tearing of the tube that connects your mouth with your stomach (oesophagus)
Dehydration (losing too much fluid)
Liver disorders (yellow skin, yellowing of the whites of the eyes, abnormal darkening of the urine or unexplained nausea, vomiting, tiredness and loss of appetite)
Aggression, feeling restless
Uneven heartbeat
Patients with dementia and Parkinson s disease These patients have some side effects more often. They also have some additional side effects:
Very common (may affect more than 1 in 10 people)
Trembling
Fainting
Accidentally falling
Common (may affect up to 1 in 10 people)
Anxiety
Feeling restless
Slow and fast heartbeat
Difficulty in sleeping
Too much saliva and dehydration
Unusually slow movements or movements you cannot control
The signs of Parkinson s disease get worse or getting similar signs such as stiff muscles, difficulty in carrying out movements and muscle weakness
Uncommon (may affect up to 1 in 100 people)
Uneven heartbeat and poor control of movements
Other side effects seen with transdermal patches and which may occur with the hard capsules:
Common (may affect up to 1 in 10 people)
Fever
Severe confusion
Urinary incontinence (inability to retain adequate urine)
Uncommon (may affect up to 1 in 100 people)
Hyperactivity (high level of activity, restlessness)
Not known (frequency cannot be estimated from the available data) Allergic reaction where the patch was used, such as blisters or skin inflammation If you get any of these side effects, contact your doctor as you may need medical assistance.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use Rivastigmine Sandoz after the expiry date which is stated on the blister, bottle and carton after EXP . The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Do not store above 30 C.
What Rivastigmine Sandoz contains
Each Rivastigmine Sandoz 1.5 mg capsule contains 1.5 mg of rivastigmine.
Each Rivastigmine Sandoz 3 mg capsule contains 3 mg of rivastigmine.
Each Rivastigmine Sandoz 4.5 mg capsule contains 4.5 mg of rivastigmine.
Each Rivastigmine Sandoz 6 mg capsule contains 6 mg of rivastigmine.
What Rivastigmine Sandoz looks like and contents of the pack
Rivastigmine Sandoz 1.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a yellow cap and yellow body, with a red imprint RIV 1.5 mg on the body.
Rivastigmine Sandoz 3 mg hard capsules, which contain an off-white to slightly yellow powder, have an orange cap and orange body, with a red imprint RIV 3 mg on the body.
Rivastigmine Sandoz 4.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a red cap and red body, with a white imprint RIV 4.5 mg on the body.
Rivastigmine Sandoz 6 mg hard capsules, which contain an off-white to slightly yellow powder, have a red cap and orange body, with a red imprint RIV 6 mg on the body.
They are packed in blisters available in three different pack sizes (28, 56 or 112 capsules) but these may not all be available in your country.
Marketing Authorisation Holder Sandoz GmbH
Biochemiestra e A-6250 Kundl
Austria
Manufacturer Novartis Farmac utica, S.A.
Gran Via de les Corts Catalanes, 08013 Barcelona
Spain
Novartis Pharma GmbH Roonstrasse 90429 N rnberg Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Sandoz N.V. Telecom Gardens, Medialaan B-1800 Vilvoorde T l/Tel: + 32 (0)2 722 97 Luxembourg/Luxemburg Sandoz N.V. Telecom Gardens, Medialaan B 1800 Vilvoorde T l/Tel: + 32 (0)2 722 97
Te .: + 359 2 970 47 Magyarorsz g Sandoz Hung ria Kft. Bart k B la t 43-H-1114 Budapest Tel.: + 36 1 430 2E-mail: info.hungary@sandoz.com
esk republika Sandoz s.r.o. Na Pankr ci 1724/CZ-14000 Praha 4 - Nusle E-mail: office.cz@sandoz.com Tel: +420 225 775 Malta Sandoz Pharmaceuticals d.d. Tel: +35699644126= Danmark Sandoz A/S Edvard Thomsens Vej DK-2300 K benhavn S Danmark Tlf: +45 6395 1info.danmark@sandoz.com
Nederland Sandoz B.V. Veluwezoom NL-1327 AH Almere Tel: + 31 36 5241E-mail: info.sandoz-nl@sandoz.com
Deutschland Hexal AG Industriestra e D-83607 Holzkirchen Tel: + 49 8024 908 0 E-mail: service@hexal.com
Norge Sandoz A/S Edvard Thomsens Vej DK-2300 K benhavn S Danmark Tlf: +45 6395 1info.norge@sandoz.com
Eesti Sandoz d.d. Eesti filiaal P rnu mnt EE-11312 Tallinn Tel: +372 6652 sterreich Sandoz GmbH Biochemiestrasse A-6250 Kundl Tel: + 43 (0)53382
Novartis (Hellas) A.E.B.E. : +30 210 281 17 Polska Sandoz Polska Sp.z o.o. ul. Domaniewska 50 C PL-02-672 Warszawa Tel: + 48 22 549 15 Espa a Sandoz Farmac utica, S.A
Centro Empresarial Parque Norte, Edificio Roble C/ Serrano Galvache N 56,
28033 Madrid Tel: +34 900 456 registros.spain@sandoz.com
Portugal Sandoz Farmac utica Lda. Avenida Professor Doutor Cavaco Silva, n. 10E Taguspark 2740-255 Porto Salvo Portugal Tel: +351 211 964 France Sandoz SAS 49, avenue Georges Pompidou F-92593 Levallois-Perret Cedex T l: + 33 1 4964 4Rom nia Sandoz S.R.L. Str Livezeni nr. 7A,
T rgu Mure , 540Rom nia Tel: +40 21 310 44 Ireland Slovenija Rowex Ltd. Newtown IE-Bantry Co. Cork P75 VTel: +353 27 50Lek Pharmaceuticals d.d. Verov kova SI-1526 Ljubljana Tel: + 386 1 5802E-mail: info.lek@sandoz.com
sland Sandoz A/S Edvard Thomsens Vej DK-2300 Kaupmannah fn S Danm rk S mi : +45 6395 1info.danmark@sandoz.com
Slovensk republika Sandoz d.d. - organiza n zlo ka i kova 22B SK-811 02 Bratislava Tel: +421 2 48 200 Italia Sandoz S.p.a
Largo Umberto Boccioni 1 I-21040 Origgio (VA) Tel: + 39 02 96Suomi/Finland Sandoz A/S Edvard Thomsens Vej DK-2300 K penhamina S/K penhamn S Tanska/Finland Puh: +358 010 6133 info.suomi@sandoz.com
Sandoz Pharmaceuticals d.d. : +357 22 69 0Sverige Sandoz A/S Edvard Thomsens Vej DK-2300 K penhamn S Danmark Tel: +45 6395 1info.sverige@sandoz.com
Latvija Sandoz d.d. Latvia fili le K.Valdem ra Str. 33 LV-1010 Riga Tel: + 371 67892United Kingdom (Northern Ireland) Sandoz GmbH Biochemiestr. A-6250 Kundl Tel: +43 5338 2uk.drugsafety@sandoz.com Lietuva Sandoz Pharmaceuticals d.d., Branch Office Lithuania Seimyniskiu Str. 3A LT-09312 Vilnius Tel: + 370 5 2636Hrvatska Sandoz d.o.o. Maksimirska 10 000 Zagreb Tel: +38512353E-mail: upit.croatia@sandoz.com
This leaflet was last revised in Detailed information on this medicine is available on the European Medicines Agency (EMA) website: http://www.ema.europa.eu
Package leaflet: Information for the patient
Rivastigmine Sandoz 2 mg/ml oral solution
rivastigmine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Entry 1 - fullUrl = Composition/composition-en-e0ec42c68686885cc176ad73b71e1d80
Resource Composition:
Generated Narrative: Composition composition-en-e0ec42c68686885cc176ad73b71e1d80
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/09/599/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - rivastigmine
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpe0ec42c68686885cc176ad73b71e1d80
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpe0ec42c68686885cc176ad73b71e1d80
identifier:
http://ema.europa.eu/identifier
/EU/1/09/599/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Rivastigmine Sandoz 1.5 mg hard capsules
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en